Scarica l'app Stockscreener
10.12
0.10%
0.010
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$10.11
Aprire:
$10.085
Volume 24 ore:
12.73M
Relative Volume:
1.30
Capitalizzazione di mercato:
$11.80B
Reddito:
$14.33B
Utile/perdita netta:
$-3.79B
Rapporto P/E:
-3.1924
EPS:
-3.17
Flusso di cassa netto:
$1.84B
1 W Prestazione:
-2.32%
1M Prestazione:
-0.20%
6M Prestazione:
+17.67%
1 anno Prestazione:
-23.22%
Intervallo 1D:
$9.92
$10.16
Intervallo di 1 settimana:
$9.92
$10.95
Portata 52W:
$6.85
$13.55
Viatris Inc Stock (VTRS) Company Profile
Nome
Viatris Inc
Settore
Telefono
(724) 514-1465
Indirizzo
1000 MYLAN BOULEVARD, CANONSBURG
Confronta VTRS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
10.12 | 11.67B | 14.33B | -3.79B | 1.84B | -3.17 |
|
ZTS
Zoetis Inc
|
120.24 | 52.69B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.66 | 43.09B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.46 | 41.90B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
23.97 | 28.06B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
448.91 | 19.55B | 3.08B | 1.24B | 1.07B | 25.61 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-15 | Iniziato | Truist | Buy |
| 2025-06-06 | Iniziato | Goldman | Neutral |
| 2024-07-19 | Ripresa | Jefferies | Buy |
| 2023-10-23 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-06-23 | Downgrade | Barclays | Equal Weight → Underweight |
| 2023-04-24 | Downgrade | Barclays | Overweight → Equal Weight |
| 2023-02-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-10 | Aggiornamento | UBS | Sell → Neutral |
| 2022-11-08 | Aggiornamento | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | Ripresa | Jefferies | Hold |
| 2022-06-14 | Iniziato | UBS | Sell |
| 2022-05-10 | Downgrade | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | Iniziato | Citigroup | Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-03-08 | Downgrade | Goldman | Buy → Neutral |
| 2021-03-02 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-02-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | Iniziato | Argus | Hold |
| 2020-12-14 | Iniziato | Bernstein | Mkt Perform |
Mostra tutto
Viatris Inc Borsa (VTRS) Ultime notizie
How Upgraded Guidance and Capital Returns at Viatris (VTRS) Have Changed Its Investment Story - Yahoo Finance
Why Viatris Inc. stock could be next big winnerWeekly Market Report & Technical Pattern Based Signals - newser.com
What does recent volatility data suggest for Viatris Inc.Take Profit & Risk Adjusted Swing Trade Ideas - newser.com
Using AI based signals to follow Viatris Inc.July 2025 PreEarnings & Risk Controlled Daily Trade Plans - newser.com
What is the fair value estimate for Viatris Inc. (VIA) stock in 2025Quarterly Trade Summary & Daily Technical Stock Forecast Reports - newser.com
What technical charts say about Viatris Inc. stock2025 Buyback Activity & Stepwise Entry and Exit Trade Signals - newser.com
Viatris Inc. (NASDAQ:VTRS) Q3 2025 Earnings Call Transcript - Insider Monkey
Viatris Nears Completion Of Company-Wide Strategic Review - Citeline News & Insights
Is it time to cut losses on Viatris Inc.Risk Management & Precise Buy Zone Tips - newser.com
Is now a turning point for Viatris Inc.Portfolio Value Summary & AI Forecasted Stock Moves - newser.com
Viatris Q3 2025 presentation slides: Raises full-year guidance despite GAAP losses - Investing.com Nigeria
Viatris Lifts Forecasts After Branded Drug Sales Outpace Estimates - Finimize
Viatris Inc. Reports Steady Q3 2025 Performance - TipRanks
Viatris, Inc. Earnings Call: Mixed Sentiment and Strategic Focus - TipRanks
Viatris: Q3 Earnings Snapshot - Stamford Advocate
3rd Circ. Won't Revive Investors' Suit Over Viatris Sale - Law360
Viatris (VTRS) Q3 2025 Earnings Call Transcript - Fortune
Can volume confirm reversal in Viatris Inc.Trade Analysis Report & Expert Approved Momentum Ideas - newser.com
Viatris Outpaces Expectations And Lifts Guidance After New Deal - Finimize
Viagra-maker Viatris beats quarterly estimates on strong demand for branded drugs - MSN
Viatris Q3 2025 presentation slides: Raises full-year guidance despite GAAP losses By Investing.com - Investing.com South Africa
Earnings call transcript: Viatris Q3 2025 beats earnings expectations, stock dips - Investing.com India
Needle-Free Devices, Technologies and Global Markets (2025-2030) Featuring Profiles of GSK, Novartis, Viatris, PharmaJet and Other Key Players - Yahoo Finance
Viatris Investors Lose Bid to Revive Biosimilars Spinoff Suit - Bloomberg Law News
Viatris Shows Improved Relative Strength; Still Shy Of Benchmark - MSN
Viatris Tops Q3 Earnings & Revenue Estimates, Ups '25 Guidance - Nasdaq
Viatris (VTRS) posts Q3 2025 results and updates 2025 guidance - AlphaStreet
Viatris (VTRS) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
Viatris raises outlook as emerging markets drive Q3 beat - MSN
Viatris Inc. Seeks M&A Opportunities - MarketScreener
Viatris raises 2025 outlook after Q3 beat (VTRS:NASDAQ) - Seeking Alpha
Viatris Reports Strong Q3 2025 Financial Results - TipRanks
Viatris (VTRS) Beats Q3 Earnings and Revenue Estimates - Yahoo Finance
(VTRS) Viatris Expects Full Year 2025 Adjusted EPS Range $2.25$2.35, vs. FactSet Est of $2.29 - MarketScreener
(VTRS) Viatris Expects Full Year 2025 Revenue Range $13.90B$14.30B, vs. FactSet Est of $13.94B - MarketScreener
Viatris Q3 Adjusted Earnings Fall, Revenue Rises; Raises 2025 Guidance - MarketScreener
Earnings Flash (VTRS) Viatris Inc. Reports Q3 Revenue $3.76B, vs. FactSet Est of $3.62B - MarketScreener
Earnings Flash (VTRS) Viatris Inc. Posts Q3 Adjusted EPS $0.67 per Share, vs. FactSet Est of $0.62 - MarketScreener
Viatris earnings beat by $0.05, revenue topped estimates - Investing.com
Viatris’s (NASDAQ:VTRS) Q3 Sales Top Estimates - Yahoo Finance
Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance - The AI Journal
Viatris : VTRS Q3 2025 Earnings PresentationFINAL - MarketScreener
Viatris Q3 revenue and adjusted EPS beat estimates, helped by Aculys Pharma acquisition - TradingView
Viatris Inc. stock outlook for YEAR2025 Market Outlook & Risk Managed Investment Signals - newser.com
United States Lipodystrophy Market 2025: Industry - openPR.com
Can Viatris Inc. (VIA) stock surprise markets with earningsWeekly Gains Summary & Smart Investment Allocation Tips - newser.com
Can Viatris Inc. stock continue upward trendRate Hike & Daily Profit Focused Screening - fcp.pa.gov.br
How Viatris Inc. stock trades during market volatilityCPI Data & Step-by-Step Swing Trade Plans - fcp.pa.gov.br
Is Viatris Inc. (VIA) stock overpriced at current multiples2025 Top Gainers & High Win Rate Trade Tips - newser.com
Will Viatris Inc. stock go up soon2025 Market Overview & Community Consensus Stock Picks - newser.com
Will Viatris Inc. stock reach Wall Street targetsEarnings Summary Report & Community Trade Idea Sharing - newser.com
Viatris Inc Azioni (VTRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):